3505-38-2 Usage
Description
Carbinoxamine Maleate Salt, also known as Clistin, is an ethanolamine-type antihistamine available as a bitter bimaleate salt. It is a white crystalline powder that is very soluble in water and freely soluble in alcohol and chloroform. Carbinoxamine is a potent first-generation antihistaminic and a competitive histamine H1 receptor antagonist. It is structurally similar to chlorpheniramine, differing only in the presence of an oxygen atom that separates the asymmetric carbon atom from the aminoethyl side chain.
Uses
Used in Pharmaceutical Industry:
Carbinoxamine Maleate Salt is used as an antihistaminic agent for treating allergic rhinitis and mild cases of Parkinson's disease. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms such as sneezing, itching, and runny nose.
Used in Medical Applications:
Carbinoxamine Maleate Salt is also used in the treatment of various allergic conditions, such as urticaria (hives) and angioedema (swelling). It helps alleviate symptoms by competing with histamine for binding to H1 receptors, thus reducing the inflammatory response.
Used in Research and Development:
Carbinoxamine Maleate Salt is utilized in scientific research to study the effects of histamine and its role in allergic reactions and other conditions. It serves as a valuable tool in understanding the mechanisms of histamine action and the development of new antihistamine drugs.
Originator
Clistin,McNeil,US,1953
Manufacturing Process
As described in US Patent 2,800,485 a solution of p-chlorophenylmagnesium
bromide is prepared by adding dropwise a solution of 230 g (1.2 mols) of p-bromochlorobenzene in 900 cc of anhydrous ether to 26.7 g (1.1 g-atoms) of magnesium suspended in 100 cc of anhydrous ether containing a small crystal
of iodine. To this solution, 107 g (1 mol) of 2-pyridinealdehyde are added
slowly with stripping at a rate to maintain refluxing. The reaction mixture is
then stirred for one hour at room temperature. The mixture is then poured
onto an equal volume of crushed ice and water and acidified with concentrated
hydrochloric acid. The ether layer is removed. The aqueous layer is made
basic with ammonia and extracted with ether. The ether solution is evaporated
and the residue dried by addition of benzene and removal by distillation to
give 208 g (95%) of solid alpha-(p-chlorophenyl)-2-pyridinemethanol melting
at 78° to 80°C. The p-chlorophenyl pyridinemethanol may alternatively be
prepared from 4-chloroacetophenone, pyridine and granular aluminum as
described in US Patent 2,606,195. In either case, the synthesis then proceeds
as described in US Patent 2,800,485.A solution of 219 g (1 mol) of α-(p-chlorophenyl)-2-pyridinemethanol in one
liter of dry toluene is heated to 100°C with stirring. Twenty-three grams (1 g-atom) of sodium are then added in portions. After all the sodium has reacted,
a dried solution of 2-dimethylaminoethyl chloride in benzene is added. This
benzene solution is prepared by dissolving 173 g (1.2 mols) of 2-
dimethylaminoethyl chloride hydrochloride in the minimum amount of water,
adding 500 cc of benzene followed by 300 g of sodium carbonate decahydrate,
stirring, separating the benzene layer and drying.The mixture is refluxed with stirring for ten hours, cooled and filtered. The
filtrate is extracted three times with 200 cc portions of 6 N acetic acid. The
aqueous acetic acid solution is then made strongly basic with 10% sodium
hydroxide solution, and extracted three times with 200 cc portions of ether.
The ether extract is dried with anhydrous sodium sulfate, stirred with 5 g of
activated carbon and filtered to provide 2-[p-chloro-α(2-dimethylaminoethoxy)
benzyl]pyridine in solution. Addition of a solution of 116 g (1 mol) of maleic
acid in 1,500 cc of ether gives 323 g (79%) of solid which, on recrystallization
from ethyl acetate, gives white solid 2-[p-chloro-α(2-dimethylaminoethoxy)
benzyl]pyridine maleate melting at 117° to 119°C.
Therapeutic Function
Antihistaminic
Check Digit Verification of cas no
The CAS Registry Mumber 3505-38-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,5,0 and 5 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 3505-38:
(6*3)+(5*5)+(4*0)+(3*5)+(2*3)+(1*8)=72
72 % 10 = 2
So 3505-38-2 is a valid CAS Registry Number.
InChI:InChI=1/C16H19ClN2O.C4H4O4/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-10,16H,11-12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/p-2/b;2-1-
3505-38-2Relevant articles and documents
Controlled release powder and process for its preparation
-
, (2008/06/13)
A controlled release powder containing discrete micro-particles for use in edible, pharmaceutical and other controlled release compositions is disclosed. The micro-particles have an average size in the range of from 0.1 to 125 μm. Each of the micro-particles is in the form of a micromatrix of an active ingredient uniformly distributed in at least one non-toxic polymer. The micro-particles have a predetermined release of active ingredient when the dissolution rate thereof is measured according to the Paddle Method of U.S. Pharmacopoeia XX at 37° C. and 75 r.p.m.
